duo presentation by
Luca Borro, 3D Specialist, 3D Biomedica Advanced Modeling and Printing Technician, Bambino Gesù Children’s Hospital, Rome, Italy
& Andrea Del Fattore, Head of the Bone Physiopathology Group, Bambino Gesù Children’s Hospital, Rome, Italy
Bioprinting is a technology that could revolutionize the biomedical field. It has already been used to engineer constructs that mimic aspects of the anatomical and structural complexity, allowing the production of perfectly functional and “biologically active” patient-specific parts.
One of the most important challenges of bioprinting is the identification of biomaterials that have adequate biocompatibility and biodegradability features to be used in clinical use in humans.
In this session we will describe some applications of 3D Bioprinting of Polycaprolactone in clinical applications and in research contexts.
We will show how Polycaprolactone can be used to 3D Bioprint patient-specific tracheal splints for the treatment of severe tracheo-bronchomalacias and we will present some preliminary results on the use of this material in bone regeneration research.
What drives you?
We are very interested in the bioprinting of bone tissue for the production of bone substitutes that can be used as a scaffold in humans.
Our research is driven by the desire to explore new ways to put biology at the service of human health.
Why should the delegate attend your presentation?
Our presentation will show how research on bone regeneration can be done through the use of modern 3D modeling and printing systems as well as scaffold functionalization. Anyone interested in regenerative medicine could certainly be interested in the subject of our presentation
What emerging technologies/trends do you see as having the greatest potential in the short and long run?
What kind of impact do you expect them to have?
Bioprinting will lead medicine to obtain functional anatomical structures potentially implantable in humans composed of autologous cellular material. This could lead to an important abatement of the transplant lists as it could be possible (in the future) to 3D Bioprint functionally organs “on demand” with patient’s cells.
What are the barriers that might stand in the way?
In vivo experimentation and regulatory aspects could constitute a barrier that could slow down the evolution of this research.
About Luca Borro
My professional history is quite strange: I’ve a degree in architecture and I specialized in advanced 3D modeling. The passion for medicine has led me to apply my skills on 3D modeling for biomedical applications.
So I started studying again and I studied 3 years Biology for Health and I am currently graduating in Medical Engineering at the University of Rome “Tor Vergata”.
Actually I’m a 3D Specialist in Bambino Gesù Children’s Hospital (Rome) where I deal with the applications of 3D Modeling, Printing and Bioprinting in Medicine.
The Bambino Gesù Paediatric Hospital (OPBG) is a Scientific Institute for Research, Hospitalization and Health Care, Italy’s main paediatric Hospital providing advanced health care for children and performing basic, clinical and translational research activities.
With its 11 Departments, covering all aspects of paediatrics care, the Hospital provides a complete range of healthcare services to children. OPBG has a total permanent staff of aprox 2,500, of which 625 physicians and biologists, involved both in clinical and in research activities. There are also aprox 50 post-graduate trainees (medical and surgical) and over 100 students and interns. Yearly clinical activities consist of aprox 27,000 inpatient admissions, 77,000 day hospital admissions, 6,000 day surgery treatments and over 1,500,000 outpatient visits. The Hospital’s clinical activities run side by side with its scientific research, aiming at constantly improving and innovating diagnostic and therapeutic procedures.